Table 2.
Comparison of Demographic, Clinical and Laboratory Parameters amongst The Postvaccinial Demyelination Cases And Control Population During The Same Period.
| CASES (N = 29) | CONTROLS (N = 87) | p-value | |
|---|---|---|---|
| Age (mean±SD) | 37.86 ± 12.34 | 30.82 ± 11.81 | 0.0069 |
| Gender, females (%) | 17 (58.6%) | 61 (70.1%) | 0.2553 |
| Optic nerve involvement at presentation | 9 (31%) | 21 (24.1%) | 0.4641 |
| Encephalopathy features | 6 (20.7%) | 2 (2.3%) | 0.0007 |
| Patients vaccinated with ChAdOx1 NCoV-19 | 27 (93.1%) | 34 out of 44 vaccinated controls (77.3%) | 0.0766 |
| CSF pleocytosis | 15 out of 25(60%) | 19 out of 61 (31.1%) | 0.0094 |
| Raised CSF protein | 12 out of 25(48%) | 11 out of 59 (18.7%) | 0.0062 |
| CSF oligoclonal bands | 6 out of 10(60%) | 32 out of 47(68%) | 0.6293 |
| ANA positivity | 6 out of 29(20.7%) | 12 out of 74(16.2%) | 0.5903 |
| CRP positivity | 6 out of 19(31.5%) | 7 out of 30(23.3%) | 0.5304 |
| MOG positivity | 10 out of 29 (34.5%) | 10 out of 69(14.5%) | 0.0257 |
| Aquaporin-4 positivity | 2 out of 29(6.9%) | 11 out of 69(15.9%) | 0.2325 |
Abbreviations: N: Number; SD: Standard deviation; CSF: Cerebrospinal fluid; ANA: Antinuclear antibody; CRP: C-Reactive Protein; MOG: Myelin Oligodendrocyte Glycoprotein.